Ascentage Pharma Group International (NASDAQ:AAPG) Sees Strong Trading Volume – What’s Next?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw unusually-high trading volume on Wednesday . Approximately 3,028 shares traded hands during trading, a decline of 7% from the previous session’s volume of 3,243 shares.The stock last traded at $26.16 and had previously closed at $23.87.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on AAPG. Oppenheimer initiated coverage on shares of Ascentage Pharma Group International in a research note on Thursday, December 4th. They set an “outperform” rating and a $45.00 price target on the stock. BTIG Research restated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Thursday, March 26th. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Finally, Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Stock Performance

The company has a fifty day moving average of $23.90 and a two-hundred day moving average of $29.50. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The business had revenue of $24.72 million for the quarter.

Institutional Trading of Ascentage Pharma Group International

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AAPG. Mirae Asset Global Investments Co. Ltd. bought a new stake in Ascentage Pharma Group International in the third quarter worth about $96,000. ABC Arbitrage SA bought a new position in shares of Ascentage Pharma Group International during the third quarter valued at approximately $204,000. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International in the third quarter worth approximately $383,000. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International during the 2nd quarter worth approximately $391,000. Finally, UBS Group AG boosted its holdings in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the period.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.